CCP Cancer UK Companion Study

Currently, there is extremely limited information regarding the risks posed by SARS-CoV-2 to patients with cancer. This study aims to understand the presentation, management and outcomes of patients with cancer. The influence of cancer type and treatment will be explored as well as comparing cancer patients with non-cancer patients. This dataset, on robust analysis, will provide valuable information that would educate as well as help inform practice for future possible outbreaks. The information may also inform the development of guidelines with regard to the care and management of cancer patients with viruses such as COVID19 and similar infectious diseases. Cancer is immunosuppressive, the nature of the immunosuppression seems to be influenced by the microbiota, and in addition pulmonary infections

NCT Number	NCT04603105
Lead Sponsor	The Clatterbridge Cancer Centre NHS Foundation Trust Collaborators: University of Edinburgh, University of Oxford, University of Liverpool
Conditions	Cancer, Covid19
Enrollment	9,000 participants
Start Date	2021-02-28
Primary Completion	2024-10-31 (estimated)
Study Completion	2025-10-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-25